Dermatology · Santa Monica, CA
NPI
1720074537
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
2730 Wilshire Blvd Ste 650
Santa Monica, CA, 90403
Phone (310) 829-4104
Groups this clinician bills Medicare through
Medicare paid, 2024
$252K
4,197 services
Medicare patients, 2024
530
Average age 75
Drug cost, 2024
$2.9M
841 prescriptions
Company payments, 2025
$414K
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul S Yamauchi was code 17003 (destruction skin lesion), 1,350 times for 169 patients. In total Paul S Yamauchi billed 4,197 services in 57 codes, and Medicare paid $252K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,350 | 169 | $5.94 | $8,018 |
| 99213 Office E&M - Established | Office | 669 | 391 | $72.55 | $49K |
| 17000 Destruction Skin Lesion | Office | 341 | 199 | $51.88 | $18K |
| 88305 Surgical Pathology Examination | Office | 334 | 156 | $42.84 | $14K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 265 | 41 | $0.71 | $189 |
| 11102 Skin Biopsy | Office | 206 | 167 | $87.82 | $18K |
| 11103 Skin Biopsy | Office | 125 | 70 | $47.80 | $5,975 |
| 99214 Office E&M - Established | Office | 119 | 107 | $105.59 | $13K |
| 96372 Injection Administration | Office | 115 | 43 | $12.36 | $1,422 |
| 99211 Office E&M - Established | Office | 107 | 27 | $20.36 | $2,178 |
| 99203 Office E&M - New | Office | 67 | 67 | $90.70 | $6,077 |
| 17004 Destruction Skin Lesion | Office | 65 | 39 | $149.04 | $9,688 |
| 99212 Office E&M - Established | Office | 59 | 46 | $50.73 | $2,993 |
| 17312 Mohs Surgery | Office | 43 | 29 | $392.14 | $17K |
| 17311 Mohs Surgery | Office | 40 | 32 | $612.66 | $25K |
By year: 2022 $255K for 3,866 services; 2023 $252K for 4,034 services; 2024 $252K for 4,197 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 334 | 156 | $42.84 | $14K |
Medicare prescription drug claims, 2024
In 2024, the drug Paul S Yamauchi prescribed most often to Medicare patients was Triamcinolone Acetonide, with 81 prescriptions and refills. In total Paul S Yamauchi wrote 841 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 81 | 86 | 62 | $801 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 76 | 82 | Under 11 | $617K |
| Clobetasol Propionate Generic | 55 | 60 | 31 | $3,900 |
| Minoxidil Generic | 54 | 115 | 12 | $329 |
| Otezla Apremilast | 33 | 41 | Under 11 | $198K |
| Sotyktu Deucravacitinib | 25 | 25 | Under 11 | $165K |
| Taltz Autoinjector Ixekizumab | 24 | 24 | Under 11 | $161K |
| Skyrizi Risankizumab-Rzaa | 24 | 60 | Under 11 | $479K |
| Ketoconazole Generic | 21 | 26 | 14 | $601 |
| Dupixent Syringe Dupilumab | 20 | 21 | Under 11 | $79K |
| Stelara Ustekinumab | 19 | 51 | Under 11 | $392K |
| Dupixent Pen Dupilumab | 19 | 19 | Under 11 | $73K |
| Tacrolimus Generic | 19 | 25 | Under 11 | $1,654 |
| Methotrexate Methotrexate Sodium | 18 | 28 | Under 11 | $308 |
| Gabapentin Generic | 18 | 23 | Under 11 | $264 |
Brand drugs: 366 claims; generic drugs: 475 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul S Yamauchi $414K ($414K in general payments such as food, travel and fees) from 39 companies. The largest payer was Lilly USA, LLC with $86K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 64 | $86K |
| Amgen Inc. AMGN | 64 | $51K |
| Janssen Biotech, Inc. JNJ | 44 | $40K |
| UCB, Inc. UCB.BR | 72 | $35K |
| Arcutis Biotherapeutics, Inc. ARQT | 27 | $32K |
| E.R. Squibb & Sons, L.L.C. BMY | 31 | $26K |
| Abbvie Inc. ABBV | 36 | $23K |
| Regeneron Healthcare Solutions, Inc. REGN | 20 | $22K |
| Kowa Pharmaceuticals America, Inc. | 16 | $19K |
| Genzyme Corporation SNY | 15 | $18K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.